If you liked this article you might like

Week Ahead: Earnings Come in Thick and Fast in a Middling First-Quarter Reporting Season
Johnson & Johnson's Weak Pharma Revenue Could Spell Doom for Rest of Sector
American Companies, Even Those Critical of Trump, Gave Big Bucks to Inauguration
Gilead, Pfizer, AbbVie Win From Lilly's Loss